

## Technology Advisory Committee B Interests Register

### Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]

Publication Date: 12 February 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Dr Sam Amin	Clinical Expert	Indirect	<p>Co-authored the international study investigating ganaxolone in CDKL5.</p> <p>Co-authoring the results of the open label extension study. This study was sponsored by Marinus pharmaceuticals.</p> <p>Chief investigator on another study investigating this compound in a another neurological condition, TSC.</p> <p>Orion has given a grant to the CDKL5UK charity. CDKL5UK has purchased an online software platform, vCreate for my hospital with the grant</p>	<p>11/04/2024</p> <p>04/05/2023</p>	N/A	It was agreed that Sam's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			<p>Sam Amin co-authored the international study investigating ganaxolone in CDKL5. He is also co-authoring the results of the open label extension study. This study was sponsored by Marinus pharmaceuticals.</p> <p>He is also chief investigator on another study investigating this compound in another neurological condition, TSC.</p> <p>Orion has given a grant to the CDKL5UK charity. CDKL5UK has purchased an online software platform, vCreate for his hospital with the grant.</p>			